Research programme: vaccines - Aventis Pasteur/MaxygenAlternative Names: Maxy-635; Vaccines research programme - sanofi pasteur/Maxygen
Latest Information Update: 10 Jun 2013
At a glance
- Originator Maxygen; sanofi pasteur
- Class Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 10 Jun 2013 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
- 10 Jun 2013 Discontinued - Preclinical for Undefined indication in France (unspecified route)
- 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur